BRAF and melanoma: Inhibitors of V600E-mutated or V600K-mutated proto-oncogene serine/threonine protein kinase B-RAF (e.g., vemurafenib or dabrafenib) suppress the proliferation of BRAF-mutated melanoma cells24 and have significantly improved patient survival25.